Assert-IQ vs Cleerly ISCHEMIA

Cleerly ISCHEMIA offers an intuitive, interactive web-based platform with comprehensive reports and seamless integration into existing radiology workflows via API, such as PowerScribe. This streamlines the experience for clinicians by fitting directly into their established processes. While Assert-IQ provides remote monitoring and a patient activator, its lack of a dedicated mobile app for clinicians or patients, and the physical insertion aspect, make Cleerly's purely software-based, integrated approach more universally 'usable' for the target clinician audience.

Cleerly ISCHEMIA provides a comprehensive, non-invasive diagnostic picture for coronary artery disease by leveraging AI to analyze CCTA scans, offering functional assessment (non-invasive FFR estimation) and detailed plaque characterization. This allows for personalized diagnosis and treatment planning, potentially reducing the need for more invasive tests. Assert-IQ offers crucial long-term continuous monitoring for arrhythmias, but Cleerly's ability to extract such detailed, actionable insights from a single non-invasive CCTA scan offers a distinct and profound clinical advantage for diagnosing and managing CAD.

Both Assert-IQ and Cleerly ISCHEMIA utilize opaque enterprise or institutional pricing models that require direct contact with the vendor for details. Neither tool offers a free trial. Without specific cost information or publicly available value propositions, it is impossible to definitively determine which offers better pricing or overall value.

Assert-IQ is a product of Abbott Medical, a global leader in medical devices with a long history and established infrastructure, which inherently suggests robust enterprise support and long-term viability. Its hybrid deployment and data export capabilities further support integration into large health systems. Cleerly ISCHEMIA, while offering strong technical readiness with its web-based platform, API integration, and secure data transfer via Cleerly Proxy, cannot match Abbott's extensive institutional experience and established enterprise relationships.

Cleerly ISCHEMIA's innovation lies in its AI-enabled CCTA analysis that non-invasively determines the likelihood of coronary artery ischemia at a vessel level, including fractional flow reserve (FFR) estimation and comprehensive coronary plaque characterization. This leverages existing imaging data to provide novel, actionable insights that traditionally required more invasive or separate tests. While Assert-IQ offers advanced algorithms and long-term continuous monitoring, Cleerly's approach represents a more transformative application of AI in non-invasive cardiac diagnostics.

As a product from Abbott Medical, Assert-IQ benefits from the extensive support infrastructure, comprehensive documentation, and established training programs of a global healthcare company. Abbott provides detailed clinician and patient manuals, as well as various customer and technical support channels. While Cleerly offers client support and educational resources, the sheer scale and proven track record of Abbott in providing robust support for medical devices give Assert-IQ a significant advantage.